

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai HeartCare Medical Technology  
Corporation Limited**

**上海心瑋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)  
(Stock Code: 6609)*

**POSITIVE PROFIT ALERT  
SUPPLEMENTAL ANNOUNCEMENT**

This announcement is made by Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated July 29, 2025 regarding, amongst other things, the positive profit alert of the Group for the six months ended June 30, 2025 (the “**Announcement**”). Unless otherwise defined, capitalized terms used herein shall have the same meaning as defined in the Announcement.

The Board wishes to supplement and inform the Shareholders and potential investors that, based on a further assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2025 (the “**Reporting Period**”) and other information currently available to the Board, the Group expects to record a net profit attributable to the Shareholders of not less than RMB40 million during the Reporting Period, such a turnaround is primarily attributable to (i) an increase in revenue driven by the newly launched hemorrhagic stroke treatment devices, as well as increase in sales of acute ischemic stroke treatment devices and other hemorrhagic stroke treatment devices; (ii) the reduction in the Group’s overall expense ratio resulting from effective cost control measures of cost of sales and administrative costs, as well as a decrease in research and development costs due to changing stages of development for the Group’s research and development projects; and (iii) an increase in fair value gain on financial assets at fair value through profit or loss.

The Company is still in the process of preparing and finalizing the interim results of the Group for the Reporting Period. The data and information contained in this announcement is only a preliminary assessment made by the Board based on the consolidated management accounts of the Group which have not been audited or reviewed by the independent auditors or the audit committee of the Company, and are subject to finalization and adjustments. Save as disclosed above, all other information as set out in the Announcement remain unchanged. This supplemental announcement is supplemental to and should be read in conjunction with the Announcement.

**Shareholders and potential investors are advised to exercise caution when dealing in securities of the Company.**

By order of the Board  
**Shanghai HeartCare Medical Technology Corporation Limited**  
**Wang Guohui**  
*Chairman of the Board*

Shanghai, August 6, 2025

*As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Ding Kui, Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.*